The aim of HERACLES-B trial is to assess the efficacy of the combination of pertuzumab and trastuzumab-emtansine (T-DM1) in HER2-amplified metastatic colorectal cancer; the trial did not reach its primary end point of ORR. The gene discussed is ERBB2; the disease is metastatic colorectal cancer.